Global Exenatide Market Overview:
Exenatide is a drug used to treat diabetes mellitus type 2 and is marketed under the brand names Byetta and Bydureon, among others. It is used in conjunction with a healthy diet, regular exercise, and possibly other anti-diabetic medications. After metformin and sulfonylureas, it is a treatment alternative. It's offered as a subcutaneous injection one hour before the first and last meals of the day.
- Used for Increasing Insulin Release from the Pancreas and Decreases Excessive Glucagon Release
- Increasing Diabetes Prevalence
- Rising Research and Development Activities
- Side Effects of Exenatide Such as Acid or Sour Stomach, Diarrhea, Heartburn, Indigestion, Nausea, and Vomiting
- Growing Health Awareness among Consumers
- Surging Demand from Developing Countries
- Straight Government Regulation
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Novo Nordisk (Denmark), Sanofi (France), Eli Lilly (United States), AstraZeneca (United Kingdom), Teva Pharmaceutical Industries (Israel), Bachem AG ( Switzerland) and Ranbaxy Laboratories Limited (India). Analyst at AMA Research see Global Players to retain maximum share of Global Exenatide market by 2026.
In March 2011, Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.
What Can be Explored with the Exenatide Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Exenatide Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Exenatide
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Exenatide market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Exenatide market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Exenatide, Suppliers and Distributors of Exenatide, Venture Capitalists and Private Equity Firms and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.